The COVID-19 Report is a compilation of coronavirus news, analysis, and insights from around the world to help life sciences and health care companies stay current in this challenging.
Nasal spray shown to be effective in reducing COVID-19 transmission
SHARES
The algae-derived Nasitrol
TM nasal spray reduced the incidence of COVID-19 in intensive care unit (ICU) workers to one percent in a clinical trial.
According to Amcyte Pharma, its Nasitrol
TM nasal spray was shown to be effective in reducing COVID-19 infections among intensive care unit (ICU) staff in an independent clinical trial.
Nasitrol is a patented nasal spray based on iota carrageenan, a sulfate polysaccharide synthesised by red algae, with demonstrated antiviral activity and clinical efficacy as a nasal spray in the treatment of the common cold. A previous study at the US’s University of Tennessee Health Science Center found that the formulation inhibits infection by SARS-CoV-2, the virus that causes COVID-19,
Published: May 03, 2021
KIRKLAND, WA – May 3, 2021 Amcyte Pharma, a Seattle-based company dedicated to the commercialization of immunomodulators, announced the results of an independent clinical trial among ICU staff suggesting that its product, Nasitrol
TM nasal spray, represents a safe and effective treatment that could prevent transmission of COVID-19. Amcyte will market Nasitrol in the U.S. through a licensing agreement from Laboratorio Pablo Cassara, an Argentinean pharma company leader in innovation.
Nasitrol is a patented nasal spray based on iota carrageenan, a sulfate polysaccharide synthesized by red algae, with demonstrated antiviral activity and clinical efficacy as a nasal spray in the treatment of the common cold. A previous study at the University of Tennessee Health Science Center found that the iota carrageenan formulation inhibits infection by SARS-CoV-2, the virus that causes COVID-19, in cell culture in vitro.